Clinical trial NCT04948827: A First-in-Human Study of SBP-9330 in Healthy Subjects
Official title: A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Smoking Cessation
Lead sponsor: Camino Pharma, LLC
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Drug Abuse (NIDA)
name: Sanford Burnham Prebys
name: University of California, San Diego
First posted: 2021-07-02
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.


Eligibility criteria: Inclusion Criteria:

1. Provision of written informed consent prior to the initiation of any protocol-specific procedures
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Healthy male or female subject ≥ 18 and ≤ 55 years of age
4. Body mass index (BMI) ≥ 18.5 kg/m2 and ≤ 32.0 kg/m2
5. Body weight ≥ 50.0 kg at Screening
6. A female subject must meet at least one of the following criteria: a. Is of childbearing potential and agrees to use an acceptable contraceptive method. b. Is of non-childbearing potential, defined as surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a postmenopausal state (i.e., at least 1 year without menses prior to the first study drug administration without an alternative medical condition and confirmed with a serum follicle-stimulating hormone \[FSH\] \> 40 IU/L at Screening)
7. Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from the first admission to the CRU until 90 days after the last study drug administration.
8. Part A and B only: Never- or nonsmoker (a nonsmoker is defined as someone who completely stopped using nicotine products for at least 2 years prior to the first study drug administration)
9. Have no clinically significant medical or mental health conditions captured in the medical history or evidence of clinically significant findings on the physical examination and/or ECG, as determined by an Investigator
10. No clinically significant abnormalities in blood pressure, heart rate, body temperature and respiratory rate and no evidence of orthostatic hypotension or postural tachycardia at Screening.

    Part C Only:
11. Are current tobacco cigarette smokers who smoke an average of 10 or more cigarettes per day in the 30 days prior to Screening
12. Expired breath CO level ≥10 parts per million (ppm) at Screening and prior to the first study drug administration
13. Positive test result for cotinine at Screening and prior to the first study drug administration
14. Are not motivated to try to quit smoking from Screening through 30 days from the first study drug administration

Exclusion Criteria:

1. Female who is lactating
2. Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration
3. Female who is planning to become pregnant during this study or within 90 days after the last study drug administration
4. Male with female partner who is pregnant, lactating, or planning to become pregnant during this study or within 90 days after the last study drug administration
5. Poor venous access as determined by an Investigator at Screening
6. History of significant hypersensitivity to SBP-9330 or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
7. Presence of any medical condition that, in the opinion of an Investigator, poses an unacceptable risk to the subjects
8. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug absorption
9. Evidence or history of clinically significant cardiovascular, pulmonary, hematologic, psychiatric (including mood and substance use disorders), neurological (including migraines, seizures, and epilepsy), endocrine, renal, hepatic, gastrointestinal, immunologic or dermatologic disease
10. History of malignancy within the past five years, except for successfully treated basal cell carcinoma of the skin
11. History of suicidal ideation or suicidal behavior as per the C-SSRS questionnaire administered at Screening
12. Evidence or history of significant psychiatric disease or any DSM-5 disorder as assessed by the Mini International Neuropsychiatric Interview (M.I.N.I.) administered at Screening
13. Routine or chronic use of more than three grams of acetaminophen daily
14. Strenuous activity, sunbathing, and contact sports within 48 hours prior to (first) admission to the CRU
15. Current alcohol consumption exceeding two standard drinks per day on average (1 standard drink=10 grams of alcohol) for male subjects and one standard drink per day on average for female subjects
16. History of alcohol or drug (other than caffeine) use disorder within 12 months prior to Screening
17. Any clinically significant illness in the 28 days prior to the first study drug administration
18. QTcF interval (QT interval corrected for heart rate according to Fridericia) \> 450 ms for males and \> 470 ms for females at Screening or on Day -1
19. Parts A and B only: Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration
20. Positive test results for HIV-1/HIV-2 antibodies, hepatitis B surface antigen or hepatitis C antibody
21. Consumption of any prescription drugs (with the exception of hormonal contraceptives or hormone replacement therapy) or over-the-counter medications and nutrients known to modulate cytochrome P450 (CYP450) enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville \[blood\] orange products) or St. John's Wort within 14 days prior to the first study drug administration
22. Consumption of other prescription and over-the-counter medication not specifically excluded by Exclusion Criterion 21 including health supplements and herbal remedies within 7 days prior to the first study drug administration (an exception is made for paracetamol \[acetaminophen\], which is allowed up to admission to the clinic).
23. Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
24. Intake of an investigational product in the 30 days or 5 half-lives (whichever is longer) prior to Screening
25. Inclusion in a previous cohort of this clinical study
26. Employee of the contract research organization (CRO) or the Sponsor.
27. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to Screening
28. Plasma donation within 7 days prior to Screening

    Part C Only:
29. History of generalized rash reaction to any drugs
30. Positive test result (except cotinine) for alcohol and/or drugs of abuse at Screening or prior to the first study drug administration
31. Use of smoking cessation aids (NRT, bupropion, or varenicline) within 30 days prior to the first study drug administration
32. Unable to abstain from smoking tobacco cigarettes for at least 1 hour before and 2 hours after study drug administration
33. Unable to abstain from using nicotine-containing products other than tobacco cigarettes (e.g., pipes, cigars, e-cigarettes or vapes, nicotine topical patches, nicotine gum, or nicotine lozenges) during the study

Primary outcomes:
measure: Number of Treatment-Emergent Adverse Events [Safety and Tolerability]
timeFrame: Part A: 8 days Part B: 21 days Part C: 21 days
Secondary outcomes:
measure: Pharmacokinetics of SBP-9330: Cmax
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: Tmax
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: AUC 0-24
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 24 hours post-dose
measure: Pharmacokinetics of SBP-9330: AUC 0-T
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: AUC 0-∞
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: T½
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: CL/F
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: Vz/F
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: C Trough
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: Cτ
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: AUCτ
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: T½, Eff
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: CL/Fss
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: Vz/Fss
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: RAC(Cmax)
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
measure: Pharmacokinetics of SBP-9330: RAC(AUC)
timeFrame: PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Other outcomes:
measure: Expired Carbon Monoxide (ECO) Level
timeFrame: Daily from Screening through Day 14
measure: Plasma Cotinine Level
timeFrame: Predose, Day 7 and Day 14
measure: Number of Cigarettes Smoked
timeFrame: Daily from Screening through Day 14
measure: Minnesota Nicotine Withdrawal Scale (MNWS)
timeFrame: Screening through Day 14
measure: Questionnaire on Smoking Urges - Brief Version (QSU-Brief)
timeFrame: Screening through Day 15
Locations:
city: Overland Park
country: United States
facility: Altasciences Clinical Kansas, Inc
state: Kansas
Study officials:
References: